Go Pro
OTCMKTS:LXRP

Lexaria Bioscience (LXRP) Stock Price, News & Analysis

Lexaria Bioscience logo

About Lexaria Bioscience Stock (OTCMKTS:LXRP)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
2.15 million shs
Average Volume
608,350 shs
Market Capitalization
$20.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Lexaria Bioscience Corp. is a biotechnology company focused on the development and commercialization of innovative drug delivery technologies. Headquartered in Vancouver, Canada, the company trades on the OTC Markets under the symbol LXRP. Lexaria’s proprietary DehydraTECH platform is designed to enhance the oral absorption of a broad range of active pharmaceutical ingredients, nutraceuticals and consumer products by improving their bioavailability and onset of action.

Central to Lexaria’s business activities is the application of its DehydraTECH technology to cannabinoid compounds such as CBD and THC, as well as nicotine and various vitamin formulations. By integrating active molecules with specific lipid-based excipients, the platform is intended to facilitate faster uptake in the bloodstream and higher overall exposure compared to unformulated ingredients. Lexaria pursues both in-house product development and licensing arrangements with established consumer goods and pharmaceutical partners.

Over the years, Lexaria has secured multiple patents for its delivery systems and has engaged in preclinical and human clinical studies to validate safety and efficacy. The company’s research spans pain management, inflammation, cardiovascular health and metabolic syndrome, reflecting its pursuit of applications beyond the botanical and nutraceutical markets. Lexaria also collaborates with academic institutions and contract research organizations to advance its pipeline and explore potential new indications.

Founded in 2011, Lexaria Bioscience is led by President and Chief Executive Officer Chris Bunka, who brings extensive experience in the biotech and cannabis sectors. Under his direction, the company continues to scale its intellectual property portfolio and expand licensing opportunities in North America, Europe and Asia. Lexaria’s strategic goal is to establish DehydraTECH as a preferred delivery solution for both established and emerging companies in the pharmaceutical, nutraceutical and consumer packaged goods industries.

AI Generated. May Contain Errors.

Receive LXRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LXRP Stock News Headlines

Lexaria Bioscience Corp
Trump and Bernie agree on this
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
See More Headlines

LXRP Stock Analysis - Frequently Asked Questions

Shares of LXRP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lexaria Bioscience investors own include Canopy Growth (CGC), Organigram Global (OGI), Walt Disney (DIS), Aurora Cannabis (ACBFF), Alibaba Group (BABA), Tilray Brands (TLRY) and NVIDIA (NVDA).

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:LXRP
CIK
1348362
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$4.09 million
Net Margins
-1,046.77%
Pretax Margin
N/A
Return on Equity
-157.62%
Return on Assets
-148.09%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
8.52
Quick Ratio
8.01

Sales & Book Value

Annual Sales
$380 thousand
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.03 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
89,587,000
Free Float
N/A
Market Cap
$20.15 million
Optionable
Not Optionable
Beta
N/A

Social Links

10 Best Stocks to Own - Fall 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (OTCMKTS:LXRP) was last updated on 9/12/2026 by MarketBeat.com Staff.
From Our Partners